Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

JOURNAL ARTICLE published May 2019 in Annals of Oncology

Research funded by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748) | Damon Runyon Cancer Research Foundation (CI-98-18)

Authors: A.J. Schoenfeld | K.C. Arbour | H. Rizvi | A.N. Iqbal | S.M. Gadgeel | J. Girshman | M.G. Kris | G.J. Riely | H.A. Yu | M.D. Hellmann